Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML.

ABSTRACT: This study aimed to evaluate the impact of the myelodysplasia-related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with NPM1-mutated (NPM1 ^mut) AML. Targeted DNA sequencing of 263 genes was performed in 568 NPM1 ^mut AML patients (median age: 59 years) entered into the prospective AMLSG 09-09 treatment trial. Most commonly co-mutated genes were DNMT3A (49.8%), FLT3-TKD (25.9%), PTPN11 (24.8%), NRAS (22.7%), TET2 (21.7%), IDH2 (21.3%), IDH1 (18%), and FLT3-ITD (17.3%). MRG mutations were identified in 18.1% of cases (18-60 years: 9.8%; >60 years: 28.7%). When focusing on the 470 patients with 2022 ELN favorable-risk NPM1 ^mut AML,

SUBMITTER: Cocciardi S 

PROVIDER: S-EPMC11733593 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature